17a-Boldenone (17a-BOL) and/or 17b-boldenone (17b-BOL) appear occasionally in fecal matter of cattle. In addition to 17a-BOL, a whole array of boldenone related substances can be found in the same samples. In vitro experiments with microsomal liver preparations and isolated hepatocytes combined with the excretion profiles found in urine and feces samples of in vivo experiments made it possible to identify several metabolites of 17b-BOL in 17b-BOL positive feces samples. In one animal treated with 17b-BOL, no 17b-BOL or its metabolites were present before treatment and most of these compounds disappeared gradually in time after the treatment was stopped. It is not clear what the origin is of 17a-BOL and boldenone metabolites in samples screened routinely for the abuse of anabolic steroids and considered to be 'negative' because of the absence of 17b-BOL since other workers showed some evidence that 17a-BOL can be of endogenous origin. However, in our hands, most of these 17a-BOL positive samples, obtained during routinely performed screenings of cattle, contained large amounts of D 4 -androstene-3,17-dione (AED), which normally is absent from routinely screened negative samples. Furthermore, AED was absent in all samples obtained from the animals treated with 17b-BOL. We have no direct evidence that 17a-BOL or 17b-BOL is of endogenous origin.
Introduction
17a-Boldenone or androsta-1,4-dien-17a-ol-3-one (17a-BOL) can occasionally be found in feces from cattle screened for the presence of illegal growth promoters. Sometimes, a trace of 17b-boldenone or androsta-1-4-dien-17b-ol-3-one (17b-BOL) can be found in the same samples. 17a-BOL is considered to be the main metabolite of 17b-BOL in human and equine urine. 1, 2 17b-BOL improves the growth and food conversion of cattle and therefore can be abused for more efficient meat production. From the analysis of application sites there is no evidence that 17b-BOL or one of its esters is used in Belgium. To our knowledge, no abuse of 17b-BOL or one of its esters has been reported in Belgium.
This provokes a series of questions about the possible origin of 17a-BOL found in field samples, the metabolic conversion of 17b-BOL in cattle and the metabolites that can be found in urine and feces after administration of 17b-BOL to cattle. The detection of 17a-BOL would become meaningful as evidence for the abuse of 17b-BOL if at the same time additional metabolites of 17b-BOL could be identified. Studies have been performed on the excretion of 17b-BOL and/or its metabolites in human and equine urine, but so far no information is available on excretion in feces. 1, 2 The excretion of boldenone metabolites in horse urine is different from the excretion profile in humans. [2] [3] [4] The main metabolic pathways in horses involve 17a-epimerisation to 17a-BOL and 16-hydroxylations. In humans, however, seven metabolites have been reported, including oxidation of 17b-hydroxy to 17-oxo, 6b-hydroxylation and reduction of the D 4 double bond and/or 3-oxo function. 1 This interspecies variation indicates the importance of studying the metabolism in cattle. A study on the metabolism in vivo of 17b-BOL in cattle performed previously was limited to the excretion of 17b-BOL and /or 17a-BOL in urine. 5 There have been no reports on other possible metabolites of 17b-BOL and/or their excretion in feces.
In this study, microsomes and isolated hepatocytes prepared from liver tissue were used to identify the most important metabolic pathways in cattle. In addition, we looked for possible metabolites of 17b-BOL in urine samples collected from one animal treated with 17b-boldenone undecanoate (obtained from R. Schilt, RIKILT-DLO, Wageningen, The Netherlands) and one animal treated with 17b-BOL (obtained from H. De Brabander, State University of Ghent, Faculty of Veterinary Medicine, Ghent, Belgium). In the latter animal we looked also for breakdown products in feces.
Experimental Materials
Microsomes were prepared from livers of two 36-week-old bulls. Hepatocytes were isolated from the liver of a FriesianHolstein bull about 1 year old.
Urine samples from animals treated with 17b-boldenone undecanoate were obtained from R. Schilt. We did not obtain any samples from this animal before treatment ( = control). Urine and feces samples of an animal (625 kg) injected intramuscularly with 700 mg of 17b-BOL were provided by H. De Brabander. From this animal we obtained samples before, during and after treatment.
All reagents and solvents were of analytical-reagent grade. Milli-Q water was prepared with a Waters Milli RO water purification system (Millipore, Bedford, MA, USA). All anabolic steroids were obtained from the Belgian national reference laboratory (Wetenschappelijk Instituut voor Volksgezondheid-Louis Pasteur, Brussels, Belgium). 5a-Androst-1-ene-3,17-dione was obtained from Sigma (St. Louis, MO, USA) and 17a-BOL from TNO (Zeist, The Netherlands). All reagents used for the isolations and incubations in vitro were obtained from Sigma. All reagents required for the synthesis of metabolites were purchased from Aldrich (Milwaukee, WI, USA).
In vitro experiments
Microsomes were prepared from liver and incubated with steroids as described earlier. 6 Hepatocytes were isolated according to the method of Seglen 7 modified by Van't Klooster et al. 8 Cells were cultured at a density of 4 3 10 6 cells per 60 mm culture dish (Greiner, Alphen a/d Rijn, The Netherlands) in 4 ml of Williams E supplemented with 4% newborn calf serum, 1.67 mmol l 21 glutamine, 50 mg ml 21 gentamicin sulfate, 1 mmol l 21 hydrocortisone, 1 mmol l 21 insulin, 0.5 mmol l 21 CaCl 2 and 0.5 mmol l 21 MgCl 2 . Cells were incubated for 4 h in a humidified atmosphere of air (95%) and CO 2 (5%) at 37 °C. The medium was then replaced with medium without serum, CaCl 2 and MgCl 2 . After an incubation of 20 h, the hepatocytes were either incubated with 100 mmol l 21 boldenone for 6 and 24 h or with 10 mmol l 21 of boldenone for 24 h. The steroids were dissolved in MeOH. The final concentration of methanol was 0.1% in the incubation medium. After incubation, the samples were frozen at 220 °C until GC-MS analysis was performed.
Sample preparation
The clean-up of urine and feces sample was carried out as described previously. 9, 10 Boldenone and its metabolites were isolated from the microsomal incubation mixtures by liquidliquid extraction. 6 For the hepatocytes, 2 ml of the incubation medium were adjusted to pH 5.2 with acetate buffer (0.2 mol l 21 , pH 4.8). A 50 ml volume of Succus Helix pomatia was added to the mixture, which was then incubated overnight at 37°C. The hydrolysed medium was applied to a Chem-Elut column (Varian, Harbor City, CA, USA). Steroids were eluted from the column with 5 ml of tert-butyl methyl ether and 5 ml of chloroform.
HPLC fractionation of extracts
The HPLC system used was equipped with a Model 231 highpressure pump (Spectra Physics, San Jose, CA, USA) with a Rheodyne (Cotati, CA, USA) Model 7010 injection valve, a Model 2151 variable wavelength monitor (LKB, Bromma, Sweden) operating at 244 nm, a Model 202 fraction collector (Gilson, Worthington, OH, USA) and a Chromatopack CR-IB recorder (Shimadzu, Kyoto, Japan). The HPLC column was a 250 3 10 mm id stainless-steel tube packed with 5 mm silica (ODS Ultrasphere, Beckman, Fullerton, CA, USA). Methanolwater was used as the mobile phase for gradient elution at a rate of 2.5 ml min 21 . The collector was operated in the time mode. Ten fractions were collected with time windows relative to naphthalene, used as an internal standard, ranging from 0.20 to 0.32 (fraction 0), 0.32 to 0.42 (fraction I), 0.42 to 0.54 (fraction II), 0.54 to 0.65 (fraction III), 0.65 to 0.75 (fraction IV), 0.75 to 0.89 (fraction V), 0.89 to 1.03 (fraction VI), 1.03 to 1.15 (fraction VII) and 1.15 to 1.27 (fraction VIII). All fractions were dried separately under a stream of nitrogen at 60 °C and the residue was dissolved in 500 ml of methanol. A 250 ml volume was placed in a GC-MS vial. 5a-Androstan-3a-ol-17-one was added as internal standard to fractions I-V and 5a-estrane3b,17a-diol to fractions VI-VIII. A 25 ml volume of a 5 ng ml 21 solution of the internal standard in methanol was added. The vials were dried under nitrogen at 60 °C and derivatised to ethoxime-trimethylsilyl derivatives. All fractions obtained were injected separately.
Gas chromatography-mass spectrometry
To produce ethoxime-trimethylsilyl (EO-TMS) derivatives, the dry residues were dissolved in 100 ml of ethoxylamine solution and heated for 90 min at 80 °C. Subsequently, the excess of reagent was evaporated at 60 °C under a stream of nitrogen. To the dry residue, 25 ml of silylating mixture (TBT) were added and the sample was incubated overnight at 80 °C. 9 Trimethylsilyl derivatives were prepared as described previously. 1 The GC-MS analyses were performed on a Finnigan (San Jose, CA, USA) GCQ system. The GC column used was a DB-5 MS fused silica column (30 m 3 0.32 mm id) with a 0.25 mm film thickness (J&W Scientific, Folsom, CA, USA). Temperature settings were as follows: injector 260 °C; transfer line 275 °C; ion source 200 °C; and oven program, initial temperature 50 °C for 20 s, increased from 50 to 190 °C at 50 °C min 21 and from 190 to 320 °C at 4.6 °C min 21 , with a hold at 320 °C for 4 min. The carrier gas was helium at a gas velocity of 60 cm s 21 .
GC-MS data handling
For positive identification of a compound, the same criteria as described earlier 9 were used. Semi-quantitative results were obtained by measuring the peak area ratio of a selected fragment ion relative to the area of one particular fragment ion of the internal standard (5 ng ml 21 ): m/z 360 of 5a-androstan-3a-ol-17-one and m/z 242 of 5a-estrane-3b,17a-diol. To calibrate the instrument, direct control samples of 10, 5, 2, 1 and 0.5 ng ml 21 were injected. Each analyte was quantified in triplicate using three different fragment ions.
Quality control of the clean-up of excreta
The overall extraction recoveries were checked for each batch of 10 samples prepared by processing a blank sample spiked with 17b-boldenone, androsta-1,4-diene-3,17-dione, 5a-androst-1-ene-3,17-dione, equilenin and some other reference standards of steroids, all at the level of 2 ng ml 21 for urine and 10 ng g 21 for feces, as described earlier. 9 An internal control for each urine and feces sample of the animal experiments and the routine feces samples was provided by the addition of equilenin at 2 ng ml 21 for urine samples and at 10 ng g 21 for feces samples. This also allowed us to correct the calculations of the excretion levels of 17b-boldenone, 17a-boldenone, androsta = 1,4-diene-3,17-dione and 5a-androst-1-ene-3,17-dione for the differences in recoveries between the samples.
Results and discussion
The liver is the main organ responsible for a wide variety of metabolic reactions of xenobiotics. Two different types of liver preparations were used to assess the hepatic biotransformation of 17b-BOL. Microsomes and monolayer cultures of isolated hepatocytes were used to allow a quick identification of important metabolites on the one hand and to reduce the need for expensive and labor-intensive animal studies on the other. Since phase I oxidative enzymes are almost exclusively localized in the endoplasmic reticulum, it is appropriate to use microsomes to study the oxidations of the steroid nucleus in a low matrix environment. The phase I oxidative biotransformation products formed are indicative of the orientation of the screening methods to be used for the analysis of urine and feces samples. However, primary cultures of hepatocytes isolated from livers of slaughtered cattle allow a more accurate quantitative study of the different metabolic routes. Moreover, the formation of metabolites can be monitored directly within the system. To evaluate the in vitro assays and their relationship to the in vivo situation, the metabolism of 4-chlorotestosterne (CLT) was also monitored.
In vitro results
The oxidation of 17b-BOL to androsta-1,4-diene-3,17-dione (ADD) was found to be the most prominent in vitro metabolite in microsomal incubations. Hydroxylation at the allylic position 6 led to some minor metabolites of both 17b-BOL and ADD. It was found that 36% of CLT, extensively metabolized in vivo, was metabolized in vitro while the same batches of microsomes metabolized only 4% of 17b-BOL, which, like CLT, is also extensively metabolized in vivo.
Incubations with isolated hepatocytes led to large amounts of 6-hydroxylated metabolites of both 17b-BOL and ADD, as shown in Fig. 1 The ion chromatograms show double peaks for ADD, 17a-BOL and 17b-BOL. Syn and anti isomers are formed with the non-sterically hindered keto groups. More details of this isomer formation is described in the literature. [11] [12] [13] In addition to the 6-hydroxylated metabolites, some other hydroxylated metabolites, which were only identified tentatively, were detected. The 17a-epimerisation product, 17a-BOL, was found to a minor extent only. ADD and 17a-BOL were identified by comparison with available compounds. 6-Hydroxy-17b-boldenone (6-HO-BOL) and 6-hydroxyandrosta-1,4-diene-3,17-dione (6-HO-ADD) were synthesized according to a method described earlier. 1 Their mass spectra are shown in Fig. 2 and the necessary data for identification are given in Table 1 . Both CLT and BOL were extensively metabolised by the monolayer cultures of isolated hepatocytes. ClT was already complety metabolised from the incubation medium after 6 h of incubation and boldenone to the extent of 88% after 24 h of incubation.
Furthermore, it was observed in primary cultures of liver cells that a limited amount only of the D 4 and 3-oxo functions of 17b-BOL and/or ADD are reduced. As an example of partial identification, two spectra are shown in Fig. 3 . The characterization of some other reduced compounds is the subject of further investigation. However, evidence for the presence of a D 1 double bond was found by oxidizing all hydroxy groups to ketones and subsequent identification of 5b-androst-1-ene-3,17-dione (5b-AED) as the main reaction product with pyridinium chlorochromate. 14 Nevertheless, this still leaves several possibilities open: 5x-androst-1-en-3x-ol-17-one or 5x-androst-1-en-3-one-17x-ol (5x-AE). 5b-AED itself, reported as a metabolite of b-BOL in human urine, was not observed after in vitro incubations (Table 1) . 5b-AED was synthesized according to the method of Schänzer and Donike. 1 .
In vivo results
Urine samples (R. Schilt) collected after administration of 17b-boldenone undecanoate were screened for all metabolites characterized during the in vitro experiments. 17b-BOL, 17a-BOL, ADD, 5b-AED and several reduction products of 17b-BOL and/or ADD were detected. The two prominent excretion products, were found to be 17a-BOL and an unidentified reduction product (5x-AEVI), eluting in HPLC fraction VI. In addition, a small amount of 6-HO-17b-boldenone was found. However, the detection of the 6-HO metabolites of ADD and 17b-BOL was hampered by strong matrix interferences. Therefore, the 6-HO-ADD and 6-HO-BOL HPLC fractions were fractionated again in smaller fractions. All fractions were analysed separately.
A similar metabolic profile was observed in the urine of the second animal (H. De Brabander). After administration, urine and feces samples were collected daily for 10 d. In urine 17a-BOL and two reduced metabolites, 5x-AEVI and 5x-AEVII, detected in HPLC fractions VI and VII, respectively, were the most prominent metabolites. ADD, 5b-AED and the HO metabolites were of minor quantitative importance. 6-HO-BOL and 6-HO-ADD were detected during the first few days only.
The quantitative and qualitative differences between the excretion in feces and urine are both striking and illustrated by the results summarized in Table 2 and 3. The hydroxy metabolites, 17b-BOL and ADD, were absent in feces. Instead, small amounts of 17a-BOL, 5b-AED and other reduced metabolites were found. In feces, the metabolite of HPLC fraction VII was detected for at least 4 d after the detection of 17a-BOL. 5b-AED was detected in feces for only 3 d and in urine for at least 10 d after administration.
Routine screening
Upon screening of routine feces samples found positive for 17a-BOL, important additional information was gained by the isolation of other metabolites. Fifty routine feces samples found positive for 17a-BOL and 19 feces samples found negative for boldenone were screened for the presence of ADD and 17b-BOL. ADD was found in all 50 17a-BOL samples but only 17 were found positive for 17b-BOL. None of the 17a-BOL negative samples were found positive for ADD nor 17b-BOL. The presence of ADD, 17b-BOL and the large amounts of 17a-BOL found are remarkable. Excreted levels as high as, e.g., 240, M = microsomes; L = isolated hepatocytes; Ax = animal experiments (x = u for urine, x = f for feces, x = u,f for urine and feces). b MM = molecular mass; MU = methylene units; EO-TMS = ethoxime-trimethylsilyl derivative; TMS = trimethylsilyl derivative. c Identification status: 1 = comparison with commercial reference product; 2 = synthesised; 3 = tentative identification from the mass spectrum. Fig. 3 Full scan EI mass spectra of the 5b-AED and two other metabolites (5x-AE) found in liver cell extracts after incubation with 17b-BOL and in vivo urine and feces samples (EOX-TMS and TMS derivatives).
24 and 632 ng g 21 were found for 17a-BOL, 17b-BOL and ADD, respectively. These findings, not corresponding with the amounts found after intramuscular administration of 17b-BOL, tend to suggest possible oral administration of boldenone or one of its esters. It is clear that further research is necessary on the dependence of the excretion profiles of boldenone metabolites on type of breed, method of application (e.g., intramuscular, oral, transdermal), type of esters and interaction with coadministered drugs. Of 15 samples positive for 17a-BOL and ADD, fractions V-VII were analysed. In these fractions spectra of 5b-AED, 5x-AEVI and 5x-AEVII were found, which further substantiates the identification of boldenone in the field samples.
Moreover, large amounts of androst-4-ene-3,17-dione (AED) were found (Fig. 4) . Levels as high as, e.g., 196 ng g 21 were present in feces samples positive for 17a-BOL and ADD. In Table 2 Urinary excretion levels of 17b-BOL and its metabolites after application of 700 mg 17b-boldenone Results based on a five point calibration curve, by injection of direct control samples from the pure standards. b Results based on a five point calibration curve, by injection of direct control samples of 5a, AED. The EO, TMS derivative of 5b-AED has a similar mass spectrum to the EO-TMS derivative of 5a, AED. c Ratio of the sum of the abundances of the masses m/z 403, 358 and 268 of the EO-TMS derivatives of 5x-AEVI or 5x-AEVII to the sum of the masses m/z 407, 332 and 242 of the internal standard (IS) 5a-estrane-3b,17a-diol (5 ng ml). d Sample collected in the afternoon (all other samples collected in the morning) of the second day after application of boldenone. Table 3 Fecal excretion levels of 17b-BOL and its metabolites after application of 700 mg 17b-boldenone only seven out of the 19 routine feces samples negative for 17a-BOL and ADD were traces of AED found. AED is present at various stages of the metabolism of steroids as an endogenous compound and as a conversion product of testosterone. 15 Physiological levels of AED were determined earlier in more than 2000 urine samples of cattle and veal calves and were found to be lower than 1 ng ml. 15 As for the presence of 17a-BOL and its metabolites, it is not clear what the origin of AED in these feces samples is. It cannot be excluded that its presence together with boldenone metabolites in the routine feces samples points to the possible co-administration (most likely oral) of naturally occurring anabolic steroids such as AED itself or testosterone with boldenone or one of its esters.
Conclusions
Several metabolites were identified after administration of 17b-BOL and after in vitro incubations with hepatocytes and subcellular fractions of bovine liver cells. We believe that some of these metabolites could be helpful in identifying the abuse of 17b-BOL for meat production in cattle.
17a-BOL has been described by Arts et al. 5 as endogenous in cattle urine. As a consequence, the identification of 17a-BOL in field samples does not demonstrate the illegal administration of 17b-BOL. According to Arts et al., 5 the administration of 17b-BOL or one of its esters is compatible with the presence of 17b-BOL at levels above 1-2 ng ml 21 in urine. 5 This rule was only applicable for the urine samples in the in vivo experiments described here. With respect to detection in feces, our results demonstrate that 17a-BOL, 17b-BOL and/or ADD are less important. None of the feces samples met the criterion. Despite the number of 17b-BOL related metabolites present, they have to be declared negative. As a consequence, it would be better to consider the reduced forms of boldenone metabolites also.
We could identify 17b-BOL metabolites, found earlier after treatment with 17b-BOL, in 17a-BOL positive routine feces samples. The presence of these metabolites of boldenone supports the identification of 17a-BOL. This additional information is important because no substantial evidence was found in Belgium for the abuse of boldenone or one of its esters in cattle breeding. Because of the possible endogenous origin of 17a-BOL and, as a consequence, also of its D 1 unsaturated bond, and the lack of substantial evidence for the abuse of boldenone or one of its esters, these samples were considered 'negative'. It is still not clear whether these 'negatives' are true negatives since we could not detect any 17b-BOL metabolite in urine and feces samples of our 17b-BOL treated animals, before treatment. If 17a-BOL can be produced endogenously, the amounts produced, most likely, are small. We therefore propose to carry out further research on boldenone metabolites to set upper limits for boldenone related substances, other than 17a-BOL and 17b-BOL, such as 5x-AEVI and 5x-AEVII in urine and feces, providing most likely additional evidence for the illegal administration of 17b-BOL.
